Faraday Pharmaceuticals to Participate in Jefferies London Healthcare Conference

SEATTLE, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the prevention of heart failure by reducing myocardial damage following acute ST-elevation myocardial infarction (STEMI) through the reduction of reperfusion injury during percutaneous coronary intervention (PCI), today announced that members of its management team will participate in one-on-one meetings at the Jefferies London Healthcare Conference taking place November 19–21, 2024.

Please contact your Jefferies representative to request a one-on-one meeting with management.

About Faraday Pharmaceuticals, Inc.
Faraday Pharmaceuticals® is a clinical-stage biopharmaceutical company focused on the prevention of heart failure by reducing myocardial damage in acute STEMI. The company was founded by Dr. Mark Roth of the Fred Hutch Cancer Center and is backed by an investor group led by ARCH Venture Partners and Polaris Partners. The company’s lead program, FDY-5301, is in a pivotal Phase 3 trial and is designed to reduce ischemia-reperfusion injury in acute STEMI, a leading cause of death and a primary cause of the development of heart failure. The company is headquartered in Seattle. For more information, visit www.faradaypharma.com or follow the company on LinkedIn.

Contact:
Brian Blackman
Chief Financial Officer
[email protected]

PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
[email protected]

You May Also Be Interested In

• American Urological Association Names Next Editor of The Journal of Urology®
• ROCKET MORTGAGE TO BE THE CLIENT PARTNER FOR AAF'S 2026-2027 NATIONAL STUDENT ADVERTISING COMPETITION
• "Fundamentals of Radiation Oncology, 4th Edition" Selected for 2026 Doody's Core Titles in Radiation Oncology